Statin therapy in chronic heart failure - Frog prince or bare frog? -

Circulation Journal

Volumn 77, Issue 4, 2013, Pages 895-897

  Kihara, Yasuki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEGA 3 FATTY ACID; PITAVASTATIN; PLACEBO; RAC PROTEIN; RAS PROTEIN; RHO FACTOR; ROSUVASTATIN; SELENOPROTEIN; UBIDECARENONE;

CELL PROLIFERATION; CONGESTIVE HEART FAILURE; DRUG RESPONSE; EDITORIAL; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; MORTALITY; MULTICENTER STUDY (TOPIC); RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION;

CARDIOTONIC AGENTS; FEMALE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; QUINOLINES;

EID: 84875510158     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-0314     Document Type: Editorial

References (15)

1. Laufs U, Liao JK. Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep 2003; 5: 372-378.
2. Ramasubbu K, Estep J, White DL, Deswal A, Mann DL. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008; 51: 415-426.
3. Brown JH, Del Re DP, Sussman MA. The Rac and Rho hall of fame: A decade of hypertrophic signaling hits. Circ Res 2006; 98: 730-742.
4. Diodati JG, Dakak N, Gilligan DM, Quyyumi AA. Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans. Circulation 1998; 98: 17-24.
5. Tousoulis D, Antoniades C, Vassiliadou C, Toutouza M, Pitsavos C, Tentolouris C, et al. Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur J Heart Fail 2005; 7: 1126-1132.
6. Sun W, Lee TS, Zhu M, Gu C, Wang Y, Zhu Y, et al. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation 2006; 114: 2655-2662.
7. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002; 8: 216-224.
8. Rauchhaus M, Clark AL, Doehner W, Davos C, Bolger A, Sharma R, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003; 42: 1933-1940.
9. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004; 43: 1439-1444.
10. Moosmann B, Behl C. Selenoprotein synthesis and side-effects of statins. Lancet 2004; 363: 892-894.
11. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, et al; CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-2261.
12. Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231-1239.
13. Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1223-1230.
14. Kameda Y, Hasegawa H, Kubota A, Tadokoro H, Kobayashi Y, Komuro I, et al. Effects of pitavastatin on pressure overload-induced heart failure in mice. Circ J 2012; 76: 1159-1168.
15. Takano H, Mizuma H, Kuwabara Y, Sato Y, Shindo S, Kotooka N, et al; on behalf of the PEARL Study Investigators. Effects of pitavastatin on Japanese patients with chronic heart failure: The Pitavastatin Heart Failure Study (PEARL Study). Circ J 2013; 77: 917-925.